18 results about "Hepatitis D" patented technology

Provided are a double-gap modified oligonucleotide and the use thereof in resisting hepatitis B viruses and hepatitis D viruses. In particular, provided is a compound, or pharmaceutically acceptable salts, hydrates or solvates thereof, wherein (a) the compound is a double-gap modified oligonucleotide, the oligonucleotide having a sequence as shown in SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5; (b) the double-gap modification refers to that each nucleoside portion in the oligonucleotide is modified in the manner as shown in formula (I); and (c) internucleoside linkages of the oligonucleotide are unmodified or modified internucleoside linkages. The double-gap modified oligonucleotide has remarkably improved antiviral activity. Pl＞SI-P2-S2-P3 (I)

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The present invention relates to the field of pharmaceutical synthesis. Disclosed is a long-lasting hepatitis virus entry inhibitor. The long-lasting hepatitis virus entry inhibitor of the present invention is used for preparing a pharmaceutical composition for treating diseases, the pharmaceutical composition being used for treating chronic hepatitis B and hepatitis D.

Provided herein are methods of treating hepatitis B and / or hepatitis D using a Na + / taurocholic acid co-transporter polypeptide (NTCP) inhibitor (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a compound of Formula (II) or a pharmaceutically acceptable salt thereof). Such methods may include reducing the concentration of hepatitis B DNA, reducing the concentration of hepatitis D DNA, reducing hepatitis B surface antigen, and reducing hepatitis B core antigen (HBcAg).

The present invention relates to the use of methylene blue in the treatment of treatment of hepatitis B (HBV) and / or hepatitis D (HDV) infection of a human patient as well as pharmaceutical compositions applicable in this treatment.

Disclosed herein are immunogenic compositions or product combinations of engineered hepatitis B and hepatitis D nucleic acids, genes, peptides, or proteins that can be used to elicit an immune response against a hepatitis B and / or hepatitis D infection. Also disclosed are methods of using the immunogenic compositions or product combinations in subjects to generate immune responses against HBV and / or HDV by administering the compositions or combinations, for example, with a nucleic acid prime and polypeptide boost approach.

The present invention provides double-Gap modified oligonucleotides and their applications in anti-hepatitis B and hepatitis D viruses. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein (a) the compound is a double-Gap modified oligonucleotide; and wherein the oligonucleotide has a sequence as shown in SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 or SEQ ID NO.5; (b) the double-Gap modification refers to that each nucleoside portion in the oligonucleotide is modified in a manner as shown in Formula I; and (c) the internucleoside bond of the oligonucleotide is an unmodified or modified internucleoside bond, wherein P1, P2, P3, S1 and S2 and specific modifications are as described in the text. The double-Gap modified oligonucleotide of the present invention has significantly improved antiviral activity. P1-S1-P2-S2-P3(I).

The present invention relates to the use of methylene blue in the treatment of Hepatitis B (HBV) and / or Hepatitis D (HDV) infection in human patients and pharmaceutical compositions suitable for such treatment.

The present invention relates to a diagnostic kit for hepatitis D, which detects an antibody against hepatitis D virus (HDV) in a sample to rapidly and accurately detect the presence or absence of HDV infection and, more specifically, to a diagnostic kit for hepatitis D, comprising a recombinant HDV antigen.

The invention relates to medicine, and more particularly to hepatology, infectious diseases and oncology, and can be used for predicting hepatitis D relapse after completion of anti-viral therapy. In a liver biopsy sample from the patient, hepatitis D virus RNA is detected using a polymerase chain reaction (PCR) method. In the event of a positive PCR result for hepatitis D virus RNA in the liver biopsy sample, irrespective of a negative PCR result for hepatitis D virus RNA in the blood serum, a relapse of hepatitis D is predicted within 4-24 weeks after completion of treatment. The method provides an increase in the accuracy of predicting hepatitis D relapse after completion of anti-viral therapy by early detection of hepatitis D virus RNA in a liver biopsy sample.

The present disclosure provides, in part, benzothia(dia)zepine compounds, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.

The present disclosure provides, in part, benzothia(dia)zepine compounds, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.

The invention relates to an anti-HBsAg antibody, an antibody fragment and application thereof in preventing and treating hepatitis D virus infection and related diseases. The present invention provides a method of neutralizing hepatitis delta virus infection comprising administering an effective amount of the antibody or antigen-binding fragment thereof to a patient in need thereof by injection or infusion.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The invention discloses an application of siRNA (small interfering Ribonucleic Acid) in preparation of a medicine for treating hepatitis. A positive-sense strand of the siRNA has a nucleotide sequence as shown in SEQ ID NO: 1, at least 85% of bases of an antisense strand of the siRNA and the positive-sense strand are complementary, and hepatitis is hepatitis D liver or hepatitis B and hepatitis D liver. The siRNA inhibits the duplication of liver D by inhibiting the concentration of HBV S protein in vivo.

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.